دورية أكاديمية

Hb Belluno [ β 111(G13)Val→Gly; β 133(H11)Val→Val ( HBB : c.335T > G;402G > C)]: Incidental Detection of a New Clinically Silent β Chain Variant During Hb A 1c Determination by High Performance Liquid Chromatography

التفاصيل البيبلوغرافية
العنوان: Hb Belluno [ β 111(G13)Val→Gly; β 133(H11)Val→Val ( HBB : c.335T > G;402G > C)]: Incidental Detection of a New Clinically Silent β Chain Variant During Hb A 1c Determination by High Performance Liquid Chromatography
المؤلفون: Pianezze, Graziano, Toniolo, Manuele, Taddei Masieri, Marina, Dolcini, Bernardetta, Ravani, Anna
المصدر: Hemoglobin; Jun2016, Vol. 40 Issue 3, p143-149, 7p
مصطلحات موضوعية: DIABETES in women, GLYCOSYLATED hemoglobin, HIGH performance liquid chromatography, GENETIC mutation, NUCLEOTIDE sequencing
مستخلص: A previously unreported β chain variant, Hb Belluno [β111(G13)Val→Gly;β133(H11)Val→Val (HBB: c.335T > G;402G > C)], was incidentally discovered in a woman suffering from diabetes, during glycated hemoglobin (Hb A1c) assay. Its presence was suspected because of a small abnormal peak with a retention time just shorter than that of normal Hb A1c. Standard high performance liquid chromatography (HPLC), capillary zone electrophoresis (CZE) and agarose gel electrophoresis did not allow to separate the variant from Hb A. The reversed phase HPLC of globin chains showed the presence of a heterozygous β-globin variant amounting to approximately 43.5% of the total β chains. Later, this variant was found in five other members of the same family and DNA sequencing analysis confirmed a β-globin gene mutation. The variant is clinically silent in all patients and showed a slight instability with both heat and isopropanol tests. The other three mutations at this locus also affect stability. Hemoglobin (Hb) variants may invalidate the results of Hb A1canalysis and could result in mismanagement of diabetes. A comment alerting the requesting clinician to the presence of the Hb variant must be appended to the Hb A1cresult. Additionally, many Hb variants can be chromatographically and/or electrophoretically silent. Therefore, when the clinician suspects a variant Hb, it is not sufficient to get a negative response from an HPLC screening test to rule it out. A dialogue with the pathologist is essential, involving exchange of information and sharing a diagnostic work-up including surveys to assess Hb stability and oxygen affinity, as much as DNA sequencing. [ABSTRACT FROM AUTHOR]
Copyright of Hemoglobin is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:03630269
DOI:10.3109/03630269.2016.1150292